Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 463,930 shares, an increase of 885.4% from the March 31st total of 47,081 shares. Based on an average daily trading volume, of 2,402,691 shares, the days-to-cover ratio is currently 0.2 days. Currently, 30.9% of the company’s shares are short sold.

Clearmind Medicine Trading Down 0.8%

Shares of NASDAQ:CMND traded down $0.01 during trading on Friday, hitting $0.81. 1,819,695 shares of the company’s stock were exchanged, compared to its average volume of 3,828,751. Clearmind Medicine has a 1-year low of $0.59 and a 1-year high of $52.40. The firm has a 50-day moving average price of $1.00 and a two-hundred day moving average price of $8.89. The firm has a market cap of $1.22 million, a P/E ratio of -0.04 and a beta of 1.32.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($3.32) EPS for the quarter.

Institutional Investors Weigh In On Clearmind Medicine

A hedge fund recently raised its stake in Clearmind Medicine stock. AdvisorShares Investments LLC lifted its holdings in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 224,378 shares of the company’s stock after buying an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned about 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 96.05% of the company’s stock.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.